Instructions and Guidelines
- Department of Health and Human Services, (RFA-HL-21-003) The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act.
Open Date: September 2, 2020
Letter of Intent Due Date: September 2, 2020
Application Due Date: October 2, 2020